Vikas Ostwal Dm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2426708/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable―gallbladder cancer: the need to define indications. Hpb, 2018, 20, 841-847.	0.1	50
2	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC). Annals of Surgery, 2019, 270, 158-164.	2.1	44
3	Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urology Annals, 2012, 4, 150.	0.3	39
4	Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor. Nuclear Medicine Communications, 2016, 37, 1030-1037.	0.5	39
5	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 845-855.	3.7	32
6	Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. Journal of Surgical Oncology, 2018, 117, 372-379.	0.8	29
7	COVIDâ€19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Medicine, 2020, 9, 8747-8753.	1.3	29
8	Initial experience of a geriatric oncology clinic in a tertiary cancer center in India. Cancer Research Statistics and Treatment, 2020, 3, 208.	0.1	22
9	Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. BMJ Open, 2021, 11, e047376.	0.8	21
10	Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant ¹⁸ FDG Uptake. Neuroendocrinology, 2021, 111, 998-1004.	1.2	19
11	Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. Journal of Gastrointestinal Cancer, 2019, 50, 298-303.	0.6	18
12	Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. Supportive Care in Cancer, 2016, 24, 2575-2581.	1.0	16
13	Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer. JAMA Oncology, 2021, 7, 436.	3.4	16
14	Signet ring colorectal carcinoma: Do we need to improve the treatment algorithm?. World Journal of Gastrointestinal Oncology, 2016, 8, 819.	0.8	15
15	Primitive Neuroectodermal Tumor of Ovary in a Young Lady, Confirmed with Molecular and Cytogenetic Results—A Rare Case Report with a Diagnostic and Therapeutic Challenge. Pathology and Oncology Research, 2012, 18, 1101-1106.	0.9	14
16	Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option. Journal of Gastrointestinal Cancer, 2016, 47, 305-312.	0.6	14
17	Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 262-267.	1.4	14
18	Ovarian Metastases of Colorectal Origin: Treatment Patterns and Factors Affecting Outcomes. Indian Journal of Surgical Oncology, 2017, 8, 519-526.	0.3	14

#	Article	IF	CITATIONS
19	Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors. Nuclear Medicine Communications, 2018, 39, 1143-1149.	0.5	14
20	A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus) Tj ETQq0 0 0 rgB 2019, 9, e028147.	T /Overloc 0.8	k 10 Tf 50 7 14
21	Revision Surgery for Incidental Gallbladder Cancer—Challenging the Dogma: Ideal Timing and Real-World Applicability. Annals of Surgical Oncology, 2021, 28, 6758-6766.	0.7	14
22	Optimal neoadjuvant strategy for signet ring cell carcinoma of the rectum—Is TNT the solution?. Journal of Surgical Oncology, 2021, 124, 1417-1430.	0.8	14
23	Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience. Journal of Gastrointestinal Oncology, 2016, 7, 380-386.	0.6	13
24	Robotic versus laparoscopic sphincterâ€preserving total mesorectal excision: A propensity caseâ€matched analysis. International Journal of Medical Robotics and Computer Assisted Surgery, 2019, 15, e1965.	1.2	13
25	Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib. Journal of Gastrointestinal Oncology, 2016, 7, 624-631.	0.6	12
26	Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine–temozolamide. Nuclear Medicine Communications, 2016, 37, 669-671.	0.5	12
27	Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. Journal of Gastrointestinal Oncology, 2018, 10, 19-29.	0.6	12
28	Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. British Journal of Radiology, 2019, 92, 20181053.	1.0	12
29	Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). Oncologist, 2022, 27, 165-e222.	1.9	12
30	Impact of histological subtype on treatment outcomes in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation. Acta Oncológica, 2018, 57, 1721-1723.	0.8	11
31	Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib. Annals of Translational Medicine, 2017, 5, 134-134.	0.7	11
32	Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?. Journal of Gastrointestinal Oncology, 2016, 7, 958-967.	0.6	10
33	Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. Journal of Gastric Cancer, 2017, 17, 21.	0.9	10
34	Learning curve analysis for lateral pelvic lymph node dissection in rectal cancers – Outcomes improve with experience. European Journal of Surgical Oncology, 2022, 48, 1110-1116.	0.5	10
35	The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2453-2455.	3.3	9
36	Treatment of advanced Gall bladder cancer in the real world—can continuation chemotherapy improve outcomes?. Journal of Gastrointestinal Oncology, 2017, 8, 368-376.	0.6	9

#	Article	IF	CITATIONS
37	Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas – are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?. Hpb, 2020, 22, 376-382.	0.1	9
38	Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience. South Asian Journal of Cancer, 2017, 06, 113-117.	0.2	9
39	Type B insulin resistance in a systemic lupus erythematosus patient. International Journal of Rheumatic Diseases, 2009, 12, 174-176.	0.9	8
40	Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious. Journal of Gastrointestinal Oncology, 2016, 7, 638-643.	0.6	8
41	PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2016, 11, 233-241.	1.5	7
42	Rectal GIST—Outcomes and viewpoint from a tertiary cancer center. Indian Journal of Gastroenterology, 2016, 35, 445-449.	0.7	7
43	Gemcitabine–cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Medical Oncology, 2018, 35, 57.	1.2	7
44	Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective. Frontiers in Oncology, 2020, 10, 400.	1.3	7
45	Towards standardization of management of gallbladder carcinoma with obstructive jaundice: Analysis of 113 cases over 10 years at a single institution. Journal of Surgical Oncology, 2021, 124, 572-580.	0.8	7
46	Role of Adjuvant Chemotherapy in Resected T2NO Gall Bladder Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 2232-2238.	0.9	6
47	Impact of delaying surgery after chemoradiation in rectal cancer: outcomes from a tertiary cancer centre in India. Journal of Gastrointestinal Oncology, 2020, 11, 13-22.	0.6	6
48	Pathological N3 Stage (pN3/ypN3) Gastric Cancer: Outcomes, Prognostic Factors and Pattern of Recurrences After Curative Treatment. Annals of Surgical Oncology, 2021, , 1.	0.7	6
49	Management of colon cancer at a tertiary referral center in India - Patterns of presentation, treatment, and survival outcomes. Indian Journal of Cancer, 2019, 56, 297.	0.2	6
50	Shared decision-making and medicolegal aspects: Delivering high-quality cancer care in India. Indian Journal of Palliative Care, 2020, 26, 405.	1.0	6
51	Supportive Measures and Finer Practice Points in 177Lu-DOTATATE PRRT for NET: Aiming for Optimal Disease Management. Journal of Nuclear Medicine, 2014, 55, 1916-1917.	2.8	5
52	Restaging after neoadjuvant chemoradiation in rectal cancers: is histology the key in patient selection?. Journal of Gastrointestinal Oncology, 2016, 7, 360-364.	0.6	5
53	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?. Journal of Gastrointestinal Cancer, 2016, 47, 381-388.	0.6	5
54	Additional chemotherapy and salvage surgery for poor response to chemoradiotherapy in rectal cancers. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 322-328.	0.7	5

#	Article	IF	CITATIONS
55	Peritoneal Carcinomatosis in Colorectal Cancers – Management Perspective Needs a Change. Clinical Colorectal Cancer, 2017, 16, e1-e6.	1.0	5
56	Pulmonary metastasectomy of colorectal cancer origin: Evaluating process and outcomes. Journal of Surgical Oncology, 2018, 118, 1292-1300.	0.8	5
57	Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent. Indian Journal of Surgical Oncology, 2021, 12, 664-670.	0.3	5
58	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. Indian Journal of Cancer, 2018, 55, 138.	0.2	5
59	Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 165-171.	0.1	5
60	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian Journal of Medical Research, 2018, 148, 284.	0.4	5
61	Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. South Asian Journal of Cancer, 2017, 06, 110-112.	0.2	5
62	Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison. American Journal of Surgery, 2022, 223, 1055-1062.	0.9	5
63	Chicken pox infection in patients undergoing chemotherapy: A retrospective analysis from a tertiary care center in India. Journal of Infection and Public Health, 2017, 10, 8-13.	1.9	4
64	A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. Journal of Gastrointestinal Cancer, 2017, 48, 100-102.	0.6	4
65	Resection of Isolated Port Site Metastasis in Gall Bladder Cancers—Careful Selection and Perioperative Systemic Therapy May Improve Outcomes. Indian Journal of Surgical Oncology, 2018, 9, 427-431.	0.3	4
66	Can CRM Status on MRI Predict Survival in Rectal Cancers: Experience from the Indian Subcontinent. Indian Journal of Surgical Oncology, 2019, 10, 364-371.	0.3	4
67	Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e70-e76.	0.7	4
68	Outcomes of exenteration in cT4 and fixed cT3 stage primary rectal adenocarcinoma: a subgroup analysis of consolidation chemotherapy following neoadjuvant concurrent chemoradiotherapy. Langenbeck's Archives of Surgery, 2021, 406, 821-831.	0.8	4
69	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. South Asian Journal of Cancer, 2017, 06, 186-189.	0.2	4
70	Lead intoxication mimicking a malignancy. Hematology/ Oncology and Stem Cell Therapy, 2011, 4, 146-147.	0.6	3
71	Multivisceral resections for rectal cancers: short-term oncological and clinical outcomes from a tertiary-care center in India. Journal of Gastrointestinal Oncology, 2016, 7, 345-353.	0.6	3
72	Role of adjuvant chemotherapy in T2NOMO periampullary cancers. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e298-e303.	0.7	3

#	Article	IF	CITATIONS
73	Laparoscopic Versus Open Approach for Intersphincteric Resection—Results from a Tertiary Cancer Center in India. Indian Journal of Surgical Oncology, 2017, 8, 474-478.	0.3	3
74	Do Acellular Mucin Pools in Resection Margins for Rectal Cancer Influence Outcomes?. Indian Journal of Surgical Oncology, 2019, 10, 515-519.	0.3	3
75	Longâ€ŧerm oncological outcomes of the sphincter preserving total mesorectal excision with varying distal resection margins. Journal of Surgical Oncology, 2021, 123, 1784-1791.	0.8	3
76	MRI features of signet ring rectal cancer. Abdominal Radiology, 2021, 46, 5536-5549.	1.0	3
77	Laparoscopic versus open resection in locally advanced rectal cancers: a propensity matched analysis of oncological and shortâ€term outcomes. Colorectal Disease, 2021, 23, 2894-2903.	0.7	3
78	Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. Indian Journal of Cancer, 2018, 55, 88.	0.2	3
79	An evaluation of early-onset fatigue and the related coping strategies in patients with gastrointestinal cancer: A prospective pilot study. Indian Journal of Cancer, 2018, 55, 162.	0.2	3
80	Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. Indian Journal of Cancer, 2017, 54, 530.	0.2	3
81	Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India. Indian Journal of Radiology and Imaging, 2017, 27, 200-206.	0.3	3
82	Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers. South Asian Journal of Cancer, 2019, 08, 166-167.	0.2	3
83	Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nuclear Medicine Communications, 2021, 42, 337-344.	0.5	3
84	Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancers. Indian Journal of Gastroenterology, 2015, 34, 310-313.	0.7	2
85	Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4. Journal of Gastrointestinal Cancer, 2020, 51, 703-708.	0.6	2
86	Curative resection for adenocarcinoma of the gastro-esophageal junction following neo-adjuvant chemotherapy—thoraco-abdominal vs. trans-abdominal approach. Langenbeck's Archives of Surgery, 2021, 406, 613-621.	0.8	2
87	Oxaliplatin-related neuropathy in Indian patients – no difference between generic and original molecules. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 271-277.	0.1	2
88	Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian Journal of Cancer, 2019, 08, 092-097.	0.2	2
89	Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. South Asian Journal of Cancer, 2018, 07, 219-222.	0.2	2
90	Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer, 2018, 55, 144.	0.2	2

#	Article	IF	CITATIONS
91	Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer, 2019, 08, 22-26.	0.2	2
92	Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India. South Asian Journal of Cancer, 2020, 09, 209-212.	0.2	2
93	Radiotherapy for locally advanced unresectable gallbladder cancer - A way forward. Journal of Cancer Research and Therapeutics, 2022, 18, 147-151.	0.3	2
94	What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?. Translational Gastroenterology and Hepatology, 2017, 2, 94-94.	1.5	1
95	Does histology dictate outcomes of locally advanced rectal adenocarcinoma with complete pathological response following neoadjuvant chemoradiation?. Journal of Radiation Oncology, 2018, 7, 85-89.	0.7	1
96	Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabineâ€Induced Handâ€Foot Syndrome: Results of a Prospective Randomized Phase III Study. Oncologist, 2020, 25, e1886-e1892.	1.9	1
97	Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report. South Asian Journal of Cancer, 2019, 08, 51-64.	0.2	1
98	Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 24-31.	0.5	1
99	Gastrointestinal Stromal Tumor – An Overview. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 809-818.	0.1	1
100	Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?. South Asian Journal of Cancer, 2020, 09, 245-249.	0.2	1
101	Red Cell Distribution Width and Gallbladder Cancer: Is It Really Useful?. Journal of Gastrointestinal Cancer, 2022, 53, 995-1005.	0.6	1
102	An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. South Asian Journal of Cancer, 0, , .	0.2	1
103	Development of a New Tool to Assess the Quality of Life of Patients with Hand–Foot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study. South Asian Journal of Cancer, 2022, 11, 019-023.	0.2	1
104	Impact of Lumen Occlusion on Outcomes in Locally Advanced Rectal Adenocarcinoma. Indian Journal of Surgery, 2021, 83, 1401-1406.	0.2	0
105	ASO Visual Abstract: Pathologic N3 Stage (pN3/ypN3) Gastric Cancer—Outcomes, Prognostic Factors, and Pattern of Recurrences after Curative Treatment. Annals of Surgical Oncology, 2021, 28, 587.	0.7	Ο
106	Adjuvant chemotherapy in stage Il–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. South Asian Journal of Cancer, 2019, 08, 160-165.	0.2	0
107	Outcomes of Radical Surgical Resections for Nonâ€metastatic Anorectal Melanomas: Experience from a Tertiary Care Centre. Colorectal Disease, 2021, , .	0.7	0
108	The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer. South Asian Journal of Cancer, 0, , .	0.2	0